{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:18:14Z","timestamp":1790309894891,"version":"4.1.0"},"reference-count":48,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV\u2010019894"],"award-info":[{"award-number":["INV\u2010019894"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV\u2010040110"],"award-info":[{"award-number":["INV\u2010040110"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Treatment of breastfeeding mothers with malaria is challenging due to the lack of information describing drug exposure in milk and the daily dose to the breastfed infant. Physiologically based pharmacokinetic (PBPK) modeling was used to predict milk\u2010to\u2010plasma (M\/P) ratios, infant daily doses (IDD) and relative infant doses (RID) for five antimalarials with clinical lactation data (chloroquine, pyrimethamine, piperaquine, mefloquine and primaquine). In all cases, RID was correctly categorized as above or below the WHO proposed cut\u2010off of 10% using two prediction models. Predicted M\/P ratios were within 2\u2010fold of observations for 63% of studies using both models (75% and 100% were within 3\u2010fold for Models 1 and 2, respectively). M\/P ratios, IDD and RID were predicted prospectively for seven antimalarials. RID was &lt;\u200910% for amodiaquine, dihydroartemisinin, proguanil, and pyronaridine, and\u2009&gt;\u200910% for lumefantrine and tafenoquine. For atovaquone, RID was &gt;\u200910% with Model 1 but not Model 2. Predicted IDD were considerably lower than licensed doses for infants except for lumefantrine (Model 2) and tafenoquine (not licensed in &lt;\u20092\u2009years). Predictions were sensitive to drug properties (plasma protein binding and lipophilicity) and milk properties (creamatocrit and pH). This analysis demonstrates the utility of PBPK to predict milk exposure in the absence of clinical lactation information. These prediction methodologies can be used, alongside any licensed dosing information for &lt;\u20091\u2009year\u2010olds, to evaluate whether a clinical lactation study is necessary and to inform drug label or policy recommendations. The ultimate goal is to better inform optimal treatment for lactating women supporting malaria eradication.<\/jats:p>","DOI":"10.1002\/psp4.13311","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T03:20:46Z","timestamp":1739244046000},"page":"738-750","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["<scp>PBPK<\/scp>\n                    \u2010Led Assessment of Antimalarial Drug Concentrations in Breastmilk: A Strategy for Optimal Use of Prediction Methods to Guide Decision Making in an Understudied Population"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6684-4287","authenticated-orcid":false,"given":"Lisa M.","family":"Almond","sequence":"first","affiliation":[{"name":"Certara Predictive Technologies, Simcyp Division  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-9237","authenticated-orcid":false,"given":"Khaled","family":"Abduljalil","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies, Simcyp Division  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7163-2633","authenticated-orcid":false,"given":"Amita","family":"Pansari","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies, Simcyp Division  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9322-9865","authenticated-orcid":false,"given":"Beata","family":"Kusmider","sequence":"additional","affiliation":[{"name":"MMV Medicines for Malaria Venture  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies, Simcyp Division  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-1970","authenticated-orcid":false,"given":"Karen","family":"Rowland Yeo","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies, Simcyp Division  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Gardner","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies, Simcyp Division  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Faisal","sequence":"additional","affiliation":[{"name":"Certara Predictive Technologies, Simcyp Division  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2893-3553","authenticated-orcid":false,"given":"Anne Claire","family":"Marrast","sequence":"additional","affiliation":[{"name":"MMV Medicines for Malaria Venture  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5671-5302","authenticated-orcid":false,"given":"Myriam","family":"El Gaaloul","sequence":"additional","affiliation":[{"name":"MMV Medicines for Malaria Venture  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-9649","authenticated-orcid":false,"given":"J\u00f6rg J.","family":"M\u00f6hrle","sequence":"additional","affiliation":[{"name":"MMV Medicines for Malaria Venture  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5912-744X","authenticated-orcid":false,"given":"Nada","family":"Abla","sequence":"additional","affiliation":[{"name":"MMV Medicines for Malaria Venture  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"\u201cWorld Malaria Report 2023 \u201d2023 https:\/\/iris.who.int\/bitstream\/handle\/10665\/374472\/9789240086173\u2010eng.pdf?sequence=1."},{"key":"e_1_2_11_3_1","unstructured":"\u201cBreastfeeding \u2013 WHO Recommendations \u201daccessed May 17 2024 https:\/\/www.who.int\/health\u2010topics\/breastfeeding#tab=tab_2."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022\u2010057988"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011449"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.12093"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1099800413498927"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12322"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008313430901"},{"key":"e_1_2_11_10_1","unstructured":"\u201cWHO Guidelines for Malaria \u201d2023 https:\/\/iris.who.int\/handle\/10665\/373339."},{"key":"e_1_2_11_11_1","unstructured":"\u201cGuidance for Industry: Enhancing the Diversity of Clinical Trial Populations \u2013 Eligibility Criteria Enrollment Practices and Trial Designs \u201d2020 https:\/\/www.fda.gov\/media\/127712\/download."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/089033402237904"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.676"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13232"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2334"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12662"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13090"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600760302"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010199018020\u201000005"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.1988.tb03334.x"},{"key":"e_1_2_11_21_1","volume-title":"Drugs and Human Lactation: A Comprehensive Guide to the Content and Consequences of Drugs, Micronutrients, Radiopharmaceuticals, and Environmental and Occupational Chemicals in Human Milk","author":"Bennett P. N.","year":"1996"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010017\u20102287\u2010z"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13013"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3168\/jds.S0022\u20100302(73)85142\u20102"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.78.3.458"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00326\u201015"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2008.03111.x"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.1987.tb03078.x"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.1986.tb02967.x"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00327\u201015"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000238566"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy235"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691\u2010198802000\u201000004"},{"key":"e_1_2_11_34_1","volume-title":"Seasonal Malaria Chemoprevention With Sulfadoxine\u2013Pyrimethamine Plus Amodiaquine in Children: A Field Guide","author":"WHO","year":"2023"},{"key":"e_1_2_11_35_1","volume-title":"Malarone (Atovaquone and Proguanil Hydrochloride) Tablets and Pediatric Tablets","author":"GlaxoSmithKline","year":"2024"},{"key":"e_1_2_11_36_1","unstructured":"Shin Poong Pharmaceutical Co. Ltd \u201cPyramax 60 mg\/20 mg Granules for Oral Suspension \u201dEuropean Medicines Agency accessed June 24 2024 https:\/\/www.ema.europa.eu\/en\/documents\/outside\u2010eu\u2010product\u2010information\/pyramax\u2010product\u2010information_en.pdf."},{"key":"e_1_2_11_37_1","unstructured":"Novartis \u201cCoartem Dispersible (Artemether\/Lumefantrine) 20 mg\/120 mg Dispersible Tablets \u201dInternational Package Leaflet accessed May 27 2024."},{"key":"e_1_2_11_38_1","unstructured":"Novartis Pharmaceuticals \u201cClinicalTrials.gov: Pharmacokinetics Safety Tolerability and Efficacy of a New Artemether\u2010Lumefantrine Dispersible Tablet in Infants and Neonates <\u20095 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria (CALINA) \u201dacccessed August 13 2024 https:\/\/clinicaltrials.gov\/study\/NCT04300309?term=calina&rank=1."},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jmwh.12611"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928\u2010020\u201009676\u20102"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14538"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.18512.2"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010198814040\u201000003"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600770916"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12574"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13195"},{"key":"e_1_2_11_47_1","unstructured":"FDA \u201cClinical Lactation Studies: Considerations for Study Design \u201d2019 https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/clinical\u2010lactation\u2010studies\u2010considerations\u2010study\u2010design."},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13214"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-024-05112-9"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.13311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T09:13:06Z","timestamp":1748337186000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.13311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/psp4.13311"],"URL":"https:\/\/doi.org\/10.1002\/psp4.13311","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"2024-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}